KYMR
Kymera Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$110.64
−0.19%Price chart
Sep 24Sep 29Oct 2Oct 7Oct 12Oct 15Oct 20Oct 23
Key dataOct 23, 2026
Open$110.85
From 52W high−13.09%
Volume107890.00
Market cap$9.20B
P/E (TTM)—
P/S (TTM)87.6x
Div yield—
Key dataOct 23, 2026
Open
$110.85
From 52W high
−13.09%
Volume
107890.00
Market cap
$9.20B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−29.5x
P/E (TTM)
—
RSI (14)
49.4
MomentumView details →
1D Return
−0.19%
YTD Return
+42.44%
SummaryUpdated Jun 1, 2026
Kymera Therapeutics, Inc. (NASDAQ:KYMR) is a biopharmaceutical company founded in 2015 and headquartered in Watertown, Massachusetts. The company went public in August 2020 and has emerged as a pioneer in the field of targeted protein degradation, a novel therapeutic approach that harnesses the body's natural cellular machinery to eliminate disease-causing proteins. Since its inception, Kymera has built a robust pipeline of small molecule protein degraders targeting both oncology and immunology indications, with multiple programs advancing through clinical trials and a strategic partnership with Sanofi for its lead IRAK4 program.
Similar companies
Latest newsMore news →
Kuehn Law, PLLC announced it is investigating whether certain officers and directors of Kymera Therapeutics, Inc. breached their fiduciary duties to shareholders.23d agoKymera Therapeutics announced presentations on KT-621, a first-in-class oral STAT6 degrader, at the European Respiratory Society and European Academy of Dermatology & Venereology Congresses.52d agoKymera Therapeutics completed enrollment in its Phase 2b atopic dermatitis trial of KT-621 about six months ahead of schedule.79d ago